European medicines agency grants orphan drug designation to cornerstone pharmaceuticals' cpi-613® (devimistat) for treatment of patients with advanced unresectable biliary tract cancer

Cranbury, nj, may 24, 2022 (globe newswire) -- cornerstone pharmaceuticals, inc. (“cornerstone” or the “company”), a company focused on rare cancer therapeutics and formerly known as rafael pharmaceuticals, today announced that the european medicines agency (ema) has granted orphan drug designation to cpi-613® (devimistat) for the treatment of advanced unresectable biliary tract cancer.
RFL Ratings Summary
RFL Quant Ranking